Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel approves 19 new West Bank settlements in major annexation push - 2Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- 3Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- 4The Main 20 Gaming Control center Ever
- 5A definitive Manual for the 5 Off-road Bicycles Available
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Monetary Wellness: Planning Tips for Independence from the rat race
- The hunt for dark matter: a trivia quiz
- Change Your Home into an Exercise center with These Famous Wellness Gadgets
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
